TrialSite News

TrialSite brings an independent, objective, and unbiased media and analysis to medical research, one of the global economy’s most vital sectors. As populations age, the need for new health products and services comes. TrialSite translates complex medical research for a wide range of subscribers from busy physicians and other health care professionals to patients (and family members) to industry.

Bookmarks

Progress: 118 %

Funding Raised

$59,250

Funding Goal

$50,001-$249,998.7

Days Remaining

55 Days

TrialSite News

TrialSite brings an independent, objective, and unbiased media and analysis to medical research, one of the global economy’s most vital sectors. As populations age, the need for new health products and services comes. TrialSite translates complex medical research for a wide range of subscribers from busy physicians and other health care professionals to patients (and family members) to industry.

Progress: 118 %

Funding Raised

$59,250

Funding Goal

$50,001-$249,998.7

Days Remaining

55 Days

Business Description

TrialSite brings a much-needed independent, objective, and unbiased media and analysis to medical research. As populations age, the need for new health products and services comes. With the move to value-based care in the United States for example comes the need for more empowered and informed consumers and patients. TrialSite publishes complex medical research for viewing by a wide range of subscribers from busy physicians and other health care professionals to patients (and family members) to industry and investors. TrialSite’s leadership continues to advance the proprietary media and social authoring platform to extend and enhance how people can share and access unbiased research information from clinical trial results to university drug discovery efforts to private equity investments in emerging science. The founder, Daniel O’Conner fully financed the company from the end of 2018 until August 2021 when it set up a paywall. A “paywall” is a method of restricting access to content to those who purchase or pay a subscription fee.
Now generating revenues, the Company intends to expand to include transparent unbiased news and information for life science investors, from private equity and VCs to institutional investors placing investments in life sciences companies. TrialSite tracks the entire ecosystem not holding back or filtering information like many other media. Moreover, we are continuously advancing the proprietary technology behind TrialSite. We have included features such as social authoring (similar to Substack or Medium) and will soon release a dynamic Q&A feature. Our goal is to continuously add compelling features to the platform so that over time it becomes a unique media and social network dedicated to medical research. Funding will help A) accelerate new features, B) expand our coverage into life science investment, and C) support subscription marketing efforts.
In a few short years, with little marketing and one founder/financier, TrialSite has become a well-known and increasingly global brand.
We seek to use the funds from this financing to continue to A) enhance the product (user/reader experience) and add more engagement features to deliver a unique asset combining elements of media, social authoring network (similar to Substack, Inc.), B) expand coverage to include investor community and C) expand marketing to drive more subscriptions.
We hope to make TrialSite a digital hub where valuable stakeholders in the global life science community come to learn, contribute and engage from health care professionals and industry to the patient advocacy community and investors
With additional funds, we hope to have 10,000 subscribers by the end of 2022 reaching between $500K to $1M in revenue. We will strive to grow to 25,000 subscribers by the end of 2023 approaching $2M in revenue. As we segment the media sections including various disease/therapeutic areas (patients, doctors, and other health care professionals, regulators, etc.) we hope to also build out the most robust, specialized investor-targeted media and social network for health & life sciences research. We believe we are poised to take off and grow with support.

Problem

A lack of transparency, objectivity, and too much bias in medical research news and information. Hierarchical models mean patients, healthcare providers, investors, and others don’t have access to a network of medical research stakeholders interested in democratizing information to empower patients, enlighten healthcare providers, help augment investor research, and competitive intelligence for the industry. TrialSite provides a novel solution introducing the first media and social platform dedicated to transparent medical research tracking research sites, biopharmaceutical sponsors, regulators, patients, and investors tracking life sciences. A $100+ billion market, medical research has hit challenging times apparent during the COVID-19 pandemic. Healthcare professionals seek to access unbiased easy to consume, summarized objective information about research breakthroughs; patients (patient advocates) also seek out objective non-jargon, trustworthy information about clinical trials while investors also seek out objective information—all stakeholders with an interest in medical research need a more transparent based platform that also grows into a horizontal medical research network—a first of its kind. Access to relevant, original content including news and insights combined with news to connect with other like-minded stakeholders to better understand unfolding research-related topics, from clinical trials to the latest observational studies to real-world evidence in a user-friendly environment represents a gap.

Solution

TrialSite provides a novel solution introducing the first media and social platform dedicated to transparent, unbiased, non-industry influenced medical research tracking research sites, biopharmaceutical sponsors, regulators, patients, and investors tracking life sciences. An independent and unbiased media platform TrialSite fills a void in the market, generates compelling original content, and offers digital engagement with authoring, dynamic question and answers, and several planned other features. For example, over 50% of physicians across the USA are now employed by health systems, hospitals, or larger practices. They don’t have a lot of time to track clinical trials of interest by reading long, complex medical journals. They appreciate our trusted and importantly, independent sources that offer research summaries showcasing the good and challenges in a candid and frank manner. Likewise, patients/patient advocacy groups and other healthcare professionals and investors active in research seek out unbiased, objective information to help them better understand complex health research challenges. Additionally, traditional medical research communications remain a hierarchical world that doesn’t necessarily democratize unbiased dependable information. TrialSite’s engagement tools including qualified self-authorship, dynamic questions and answers, and more planned features represent a new paradigm in democratizing medical research information.

Business Model

A few-year-old startup, TrialSite generates revenue via subscriptions. We plan to expand this subscriber base across therapeutic areas, provider specialists, industry, and investor communities. Moreover, while TrialSite hasn’t generated revenue by advertising the Q&A function for example is open access and further revenues can be generated via advertising. TrialSite also generates some revenue via advertising on the YouTube platform. With expanding content, traffic, and classes of subscribers TrialSite forecasts a robust revenue model. While we do not censor or sell data, we continue to collect rich data about user/traffic trends by therapeutic area, location, and potentially other attributes such as demographics. Over time this might be another source of revenue.

Traction & Customers

With additional funds, we will target 10K subscribers by end of 2022 reaching between $500K to $1m. We will strive to grow to 25,000 subscribers by the end of 2023 approaching $2m in revenues. As we segment the sections including various disease/therapeutic areas (patients, doctors, and other health care professionals, regulators, etc.), we will build out the most robust, specialized investor-targeted media and social network for health & life sciences research. Today, most online startups can’t generate revenue via subscription. We believe we are poised to take off and grow with support.

Investors

The founder fully financed the company from the end of 2018 until August 2021 when we set up a paywall.

Terms

This is an offering of Class B Non-Voting Common Stock, under registration exemption 4(a)(6), TrialSite Inc. This offering must raise at least $50,001 by December 1st, 2022 at 11:59 pm ET. If this offering doesn’t reach its target, then your money will be refunded. TrialSite may issue additional securities to raise up to $249,998,7 the offering’s maximum.

Risks

See Offering Statement; A crowdfunding investment involves risk. You should not invest any funds in this offering unless you can afford to lose your entire investment.
In making an investment decision, investors must rely on their examination of the issuer and the terms of the offering, including the merits and risks involved. These securities have not been recommended or approved by any federal or state securities commission or regulatory authority. The U.S. Securities and Exchange Commission does not pass upon the merits of any securities offered or the terms of the offering, nor does it pass upon the accuracy or completeness of any offering document or literature.
These securities are offered under an exemption from registration; however, the U.S. Securities and Exchange Commission has not made an independent determination that these securities are exempt from registration.
Neither PicMii Crowdfunding nor any of its directors, officers, employees, representatives, affiliates, or agents shall have any liability whatsoever arising from any error or incompleteness of fact or opinion in, or lack of care in the preparation or publication of, the materials and communication herein or the terms or valuation of any securities offering.
The information contained herein includes forward-looking statements. These statements relate to future events or future financial performance and involve known and unknown risks, uncertainties, and other factors that may cause actual results to be materially different from any future results, levels of activity, performance, or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties, and other factors, which are, in some cases, beyond the company’s control and which could, and likely will materially affect actual results, levels of activity, performance, or achievements. Any forward-looking statement reflects the current views with respect to future events and is subject to these and other risks, uncertainties, and assumptions relating to operations, results of operations, growth strategy, and liquidity. No obligation exists to publicly update or revise these forward-looking statements for any reason or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

Security Type:

Equity Security

Price Per Share

$2.10

Post Money Valuation:

$11,850,636

Regulatory Exemption:

Regulation Crowdfunding – Section 4(a)(6)

Deadline:

December 1, 2022

Minimum Investment Amount:

$252

Target Offering Range:

$50,001-$249,998.7

*If the sum of the investment commitments does not equal or exceed the minimum offering amount at the offering deadline, no securities will be sold and investment commitments will be cancelled returned to investors.

Market Projection

Based on trends in the politicization of medical research, concerns about bias, and industry influence over medical journals and trade publications, Trial Site is part of a trend in the democratization of medical and health research. We expect that trend only to intensify.

Competition

TrialSite doesn’t have direct competition for what it does but there is substantial overlap. For example, CenterWatch offers news, information, and paid insight into medical research while medical journals offer myriad study articles. Trade publications are specialized and not patient-friendly and are heavily influenced by industry. In fact, all medical research news, journals, and trade press are heavily influenced by industry. News media more critical of the pharmaceutical industry tend to be biased, and anti-pharma with a political or ideological agenda. TrialSite has neither.

  • Last active: 4 months ago
  • 25 members
  • 0 posts
TrialSite News
  • Group
  • Daniel OConnor
  • TrialSite brings a much-needed independent, objective, and unbiased media and analysis to medical research. As populations age, the need for new health products and services comes. With the move to value-based care in the United States for example comes the need for more empowered and informed consumers and patients. TrialSite publishes complex medical research for viewing by a wide range of subscribers from busy physicians and other health care professionals to patients (and family members) to industry and investors. TrialSite’s leadership continues to advance the proprietary media and social authoring platform to extend and enhance how people can share and access unbiased research information from clinical trial results to university drug discovery efforts to private equity investments in emerging science. The founder, Daniel O’Conner fully financed the company from the end of 2018 until August 2021 when it set up a paywall. A “paywall” is a method of restricting access to content to those who purchase or pay a subscription fee. Now generating revenues, the Company intends to expand to include transparent unbiased news and information for life science investors, from private equity and VCs to institutional investors placing investments in life sciences companies. TrialSite tracks the entire ecosystem not holding back or filtering information like many other media. Moreover, we are continuously advancing the proprietary technology behind TrialSite. We have included features such as social authoring (similar to Substack or Medium) and will soon release a dynamic Q&A feature. Our goal is to continuously add compelling features to the platform so that over time it becomes a unique media and social network dedicated to medical research. Funding will help A) accelerate new features, B) expand our coverage into life science investment, and C) support subscription marketing efforts. In a few short years, with little marketing and one founder/financier, TrialSite has become a well-known and increasingly global brand. We seek to use the funds from this financing to continue to A) enhance the product (user/reader experience) and add more engagement features to deliver a unique asset combining elements of media, social authoring network (similar to Substack, Inc.), B) expand coverage to include investor community and C) expand marketing to drive more subscriptions. We hope to make TrialSite a digital hub where valuable stakeholders in the global life science community come to learn, contribute and engage from health care professionals and industry to the patient advocacy community and investors With additional funds, we hope to have 10,000 subscribers by the end of 2022 reaching between $500K to $1M in revenue. We will strive to grow to 25,000 subscribers by the end of 2023 approaching $2M in revenue. As we segment the media sections including various disease/therapeutic areas (patients, doctors, and other health care professionals, regulators, etc.) we hope to also build out the most robust, specialized investor-targeted media and social network for health & life sciences research. We believe we are poised to take off and grow with support.

Daniel O’Connor
Director and Officer
BackgroundOver 20+ years working in the software sector with a focus on biopharmaceutical/FDA regulated and healthcare industry. The founder of multiple startups including one company developing FDA compliant clinical trials document management systems (Zorch Software) acquired by a publicly traded company and merged into Computer Sciences Corp (now DXC Technologies). Earned Juris Doctor from University of California, Hastings College of Law & MA University of California, Los Angeles. BA degree from San Francisco State University.

Legal Company Name

TrialSite News

Location

1013 Centre Road
Suite 403-B
Wilmington, Delaware 19805

Number of Employees

10

Incorporation Type

C-Corp

State of Incorporation

Delaware

Date Founded

April 30, 2021

Bookmarks

Educational Material

Regulation
March 15, 2021

Make Way Venture Capitalists – SEC Updates Regulation Crowdfunding

Some Background It is no secret that venture capitalists dominate the startup space. Most startups move forward at the whim of venture capitalists just to survive. And just as you…
Regulation
February 15, 2021

The Form C

Form C - Everything You Need to Know Form C is a critical step in the crowdfunding process for all companies raising under Regulation Crowdfunding. Form C is a disclosure…
Types of SecuritiesGeneral
March 17, 2020

Types Of Securities

Types Of Securities Why do I care about the different security types available to me? Now that you are finding your inner venture capitalist, its critical that you understand what…